Revenue segments as reported by the company.

U.S. Pharmaceutical

Prescription Technology Solutions

Medical-Surgical Solutions

International

Corporate

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, distribution, general, and administrative expenses

Claims and litigation charges, net

Restructuring, impairment, and related charges, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

McKesson

McKesson Corp. engages in the provision of supply chain management solutions, retail pharmacy, community oncology and specialty care, and healthcare information technology. It operates through the following segments: U.S. Pharmaceutical, International, Medical-Surgical Solutions, and Prescription Technology Solutions (RxTS). The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products, provides practice management, technology, clinical support, and business solutions to community-based oncology, and other specialty practices, and sells financial, operational, and clinical solutions to pharmacies and provides consulting, outsourcing, technological, and other services. The International segment provides distribution and services to wholesale, institutional, and retail customers in European countries and Canada. The Medical-Surgical Solutions segment offers medical-surgical supply distribution, logistics, and other services to healthcare providers, including physician offices, surgery centers, nursing homes, hospital reference labs, and home health care agencies. The RxTS segment brings together CoverMyMeds, RelayHealth, RxCrossroads, and McKesson Prescription Automation, including Multi-Client Central Fill as a Service, to serve biopharma and life sciences partners and patients. The company was founded by John McKesson and Charles Olcott in 1833 and is headquartered in Irving, TX.

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Earnings data Q3 2025

McKesson reports robust fiscal 2023 performance and focuses on sustainability

McKesson's Q4 fiscal 2023 earnings call highlighted strong financial performance, strategic priorities, and a focus on sustainability and employee recognition. The company faces challenges related to operational efficiencies and managing potential impacts from industry dynamics. However, it remains optimistic about opportunities for long-term growth and partnerships in the oncology space.

McKesson reports strong Q1 performance and anticipates sustained growth

McKesson's Q1 fiscal 2024 earnings call showcased strong financial performance, with a focus on prescription volume growth and expansion in the U.S. Oncology Network. The company faces potential fluctuations and timing challenges in its RxTS business but expects to benefit from volume-related factors and continual development. Overall, McKesson is well-positioned for sustainable growth and value creation.

McKesson excels in Q3, eyes oncology growth and sustainability

McKesson's Q3 performance was strong, with raised guidance and progress in strategic priorities.
The company's strengths lie in its focus on oncology, sustainability initiatives, and operational performance.
Challenges include macroeconomic factors, biosimilar management, and margin improvement strategies.
Opportunities in oncology growth, biosimilars, and strategic partnerships pave the way for future success.

McKesson reports robust earnings, poised for sustainable growth in healthcare

McKesson's Q4 2023 earnings call highlighted strong financial performance, strategic advancements, and a commitment to driving sustainable growth in key healthcare segments.
The company's focus on efficiency, sustainability, and employee engagement underpins its competitive strengths and resilience in a dynamic healthcare landscape.
While challenges such as industry fluctuations and regulatory dynamics exist, McKesson's strategic positioning, diverse business lines, and growth opportunities position it for continued success.
By leveraging opportunities in service expansion, biosimilars, and market trends, McKesson aims to enhance patient outcomes, drive revenue growth, and maintain its leadership in the healthcare services sector.

McKesson exceeds Q1 expectations, focuses on supply chain efficiency

McKesson delivered strong first-quarter results, exceeding revenue and earnings expectations.
The company's focus on enhancing supply chain efficiency and expanding relationships with manufacturers is driving growth.
Challenges include non-linear investments and the impact of 340B on pharmaceutical distribution business.
Opportunities lie in benefiting from volume-related factors, supporting product life cycles, and expanding oncology solutions.

McKesson excels in Q2, anticipates growth amid strategic investments

McKesson's Q2 performance reflects strong revenue growth and operational excellence across key segments.
The company's focus on employee well-being, technology solutions, and strategic investments positions it for continued success.
While facing competitive challenges in generics procurement, McKesson maintains stability and customer-centric supply.
Anticipated growth opportunities in fiscal 2024 and beyond underscore McKesson's commitment to innovation and operational efficiency.

McKesson reports robust Q3 earnings, eyes growth through strategic investments

McKesson's Q3 performance reflects strong revenue and earnings growth, supported by strategic initiatives and investments in key segments. While facing challenges like patient visit volumes and margin pressures, the company remains focused on driving sustainable growth and value delivery. Opportunities for growth through technology investments and segment expansions position McKesson for future success.

McKesson reports robust Q4 results, eyes growth in oncology services

McKesson's strong performance in Q4 '24 underscores its leadership in oncology and biopharma services, supported by strategic investments in AI and a new partnership with Optum. While facing challenges in pricing dynamics and 3PL business growth, the company is well-positioned to capitalize on opportunities in inorganic growth, AI utilization, and health equity initiatives.

McKesson reports solid Q1 growth, focuses on pharma innovation

McKesson's Q1 2025 showed solid revenue growth and increased earnings per share, driven by strong performance in pharmaceutical segments.
While facing challenges in the Medical-Surgical segment, the company aims to leverage strengths in distribution and technology investments for future growth.
Opportunities lie in capitalizing on pharmaceutical segment performance and driving innovation through technology investments.
Overall, McKesson's outlook for fiscal 2025 remains positive with projected revenue and profit growth.

McKesson posts record revenue, focuses on oncology for sustained growth

McKesson's strong financial performance and raised guidance reflect its resilience and strategic focus on growth.
While facing regulatory and integration challenges, the company's commitment to innovation and employee well-being positions it well for the future.
Opportunities lie in expanding market presence through acquisitions, influencing policy reforms, and optimizing operational efficiencies.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

McKesson Corp. engages in providing healthcare services. It operates through the following segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs. The RxTS segment offers prescription price transparency, benefit insight, dispensing support services, third-party logistics, and wholesale distribution. The Medical-Surgical Solutions segment provides medical-surgical supply distribution, logistics, and other services to healthcare providers. The International segment refers to the distribution and services to wholesale, institutional, and retail customers in Europe and Canada. The company was founded by John McKesson and Charles Olcott in 1833 and is headquartered in Irving, TX.

McKesson (MCK) reported earnings 30 days ago. What's next for the stock?

McKesson (MCK) Up 7.7% Since Last Earnings Report: Can It Continue?

Archer-Daniels-Midland Company

J.B. Hunt Transport Services

Republic Services

TotalEnergies SE

Dividend growth stocks like TotalEnergies, J.B. Hunt, Archer-Daniels-Midland, McKesson and Republic Services seem like solid choices for September.

5 Dividend Growth Stocks to Beat September Slump

Ally Financial

Citigroup

Floor & Decor Holdings

Nu Holdings

The Oracle of Omaha has added a bunch of stocks that have lost value lately, but this one is standing out with its performance.

This Stock Is Warren Buffett's Best 2022 Buy

Cardinal Health

CF Industries Holdings

Corteva Inc

Enphase Energy

Lamb Weston Hlds

Mosaic

Nielsen Hlds

Vertex Pharmaceuticals

It's been almost all about energy stocks in the S&P 500 this year. But not entirely.

10 Stocks (Not In The Energy Sector) Are Up 30% Or More This Year

Activision Blizzard

Chevron

Occidental Petroleum

Warren Buffett likes to talk about buying more S&P 500 stocks when they're cheaper. But it turns out he's human, too.

Warren Buffett Boldly Loads Up On 4 Of His Best Stocks

Northrop Grumman

Should investors be watching these defensive stocks this week?

3 Defensive Stocks To Watch In August 2022

ArcBest

Dollar General

Top-ranked dividend stocks like TotalEnergies (TTE), ArcBest (ARCB), Dollar General (DG), McKesson (MCK) and Archer-Daniels-Midland (ADM) are worth adding to your portfolio.

Dividend Growth Investing in Vogue: 5 Stock Picks

Apple

Celanese

Markel

Paramount Global

Berkshire Hathaway revealed what stocks it snapped up in the second quarter.

9 Stocks Warren Buffett Just Bought in the Second Quarter

You might need to have a good deal of patience if you invest.

This Indestructible Buffett Stock Is Soaring, But Is It a Buy?

AbbVie

AmerisourceBergen

Bristol-Myers

Quest Diagnostics

HCA Healthcare

Labcorp Holdings Inc

Merck

Pfizer

Viatris

The S&P 500 Index has rallied 10% since June 22 from a deep decline, but there are different schools of thought about whether investors are out of the woods yet.

10 defensive stocks that can also provide you with growth and dividends over the long term

So far, 2022 has been challenging, with the S&P 500 declining 25% while tech stocks have been tanking.  But here's a news flash for you — this is part and parcel of an investor's life.

This Lesser-Known Stock Has Moved 35% Since My Last Update, Here's What I'm Waiting For Next

Are these high-flying Buffett stocks still smart picks to buy now?

3 Warren Buffett Stocks to Buy That Have Soared 31% to 104% This Year

We expect MCK to outperform the broader market in the near term, as the demand for its products and services is relatively independent of consumer sentiment. Most of the firm's revenues are generated by the U.S. pharmaceutical segment, reducing the potential foreign exchange headwinds for the company.

3 Reasons Why McKesson Could Be An Attractive Play During A Downturn

McKesson's (MCK) fiscal first-quarter 2023 results benefit from segmental growth.

McKesson's (MCK) Q1 Earnings and Revenues Beat Estimates

McKesson Corporation (NYSE:MCK ) Q1 2023 Earnings Conference Call August 3, 2022 4:30 PM ET Company Participants Rachel Rodriguez – Vice President of Investor Relations Brian Tyler – Chief Executive Officer Britt Vitalone – Chief Financial Officer Conference Call Participants Lisa Gill – J.P. Morgan Michael Cherny – Bank of America Steven Valiquette – Barclays Eric Percher – Nephron Research Ricky Goldwasser – Morgan Stanley Kevin Caliendo – UBS Eric Coldwell – Baird Charles Rhyee – Cowen Brian Tanquilut – Jefferies Operator Please stand by.

McKesson Corporation's (MCK) CEO Brian Tyler on Q1 2023 Results - Earnings Call Transcript

McKesson (MCK) delivered earnings and revenue surprises of 9.79% and 5.14%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

McKesson (MCK) Tops Q1 Earnings and Revenue Estimates

McKesson raised its full-year earnings outlook Wednesday following a quarterly beat. McKesson stock advanced in late action.

Drug Distributor McKesson Offers Clean Beat, Raises Earnings Outlook

IRVING, Texas--(BUSINESS WIRE)--McKesson Corporation (NYSE: MCK) has released its fiscal 2023 first-quarter financial results. Results can be accessed on McKesson's Investor Relations website at investor.mckesson.com/financials/quarterly-results. As previously announced, the company will host a live webcast of the earnings conference call for investors today, Wednesday, August 3rd at 4:30 PM ET to review its financial results. The audio webcast of the conference call will be available live and

McKesson Corporation Reports Fiscal 2023 First-Quarter Results

Here is how McKesson (MCK) and argenex SE (ARGX) have performed compared to their sector so far this year.

Is McKesson (MCK) Outperforming Other Medical Stocks This Year?

Ford Motor Company

Hershey

Ford Motor lifted its quarterly dividend to 15 cents a share, a 50% boost, while Hershey raised its payout by 15%.

Ford Motor, Hershey, and McKesson Just Raised Their Dividends

McKesson (MCK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate McKesson (MCK) to Report a Decline in Earnings: What to Look Out for

DaVita

Johnson & Johnson

These unstoppable companies can succeed in pretty much any economic condition.

3 No-Brainer Warren Buffett Stocks That Will Undeniably Profit from the Bear Market

McKesson stock briefly broke out Monday after the drug distributor raised its dividend and announced a new deal for a cancer-related drug. The post Red-Hot Medical Stock McKesson Tacks Onto Its 35% Gain With A Brief Breakout appeared first on Investor's Business Daily.

Red-Hot Medical Stock McKesson Tacks Onto Its 35% Gain With A Brief Breakout

McKesson Corp. MCK, +0.80% said Monday its board has raised its quarterly dividend by 15% to 54 cents a share from 47 cents previously. The new dividend is payable Oct. 3 to shareholders of record as of Sept.

McKesson raises quarterly dividend by 15% to 54 cents a share from 47 cents

IRVING, Texas--(BUSINESS WIRE)--The Board of Directors of McKesson Corporation (NYSE:MCK) declared on July 22, 2022 a regular dividend of $0.54 per share of common stock, a 15% increase from $0.47 per share in the prior quarter. The dividend will be payable on October 3, 2022, to stockholders of record on September 1, 2022. “This dividend increase demonstrates our continued commitment to returning capital to shareholders as part of our disciplined capital allocation framework,” said Brian Tyler

News for McKesson Stock (MCK)